What are CHE's growth prospects?
Equity research analysts project steady long-term growth prospects for Chemed Corporation, anchored by the consistent operational performance of its two primary operating segments: VITAS Healthcare and Roto-Rooter. Financial forecasts anticipate reliable annual revenue compounding and double-digit earnings per share expansion, supported by increasing patient admissions and average daily census growth within its hospice care division, alongside ongoing demand for plumbing and drain cleaning services. Management's disciplined share repurchase programs and healthy balance sheet provide additional support for balanced shareholder returns.
Related FAQs
Chemed Corporation officially finalized its acquisition of VITAS Healthcare Corporation on February 24, 2004.
Chemed Corporation trades at a price-to-earnings ratio of approximately 22.5 to 24.6, sitting comfortably below its 10-year historical average.
Chemed Corporation provides specialized, non-acute healthcare services through its primary operating subsidiary, Vitas Healthcare, which is the nation's largest provider of hospice care in the United States.
The corporate brand name Chemed (referring to Chemed Corporation) originated historically as a portmanteau abbreviation combining linguistic elements of Chemical and Medical enterprises during its early corporate evolution.
Chemed Corporation belongs to the Healthcare sector.
Chemed Corporation is a diversified operational holding company headquartered in Cincinnati, Ohio, that manages two core wholly-owned subsidiary enterprises.
Chemed Corporation operates across two distinct business segments, each facing dedicated industry rivals.
Chemed Corporation is a diversified operational enterprise that manages prominent subsidiary companies operating primarily in specialized healthcare and residential services, most notably VITAS Healthcare (the largest provider of hospice care in the ...
Wall Street analyst consensus price targets for Chemed Corporation (NYSE: CHE) average approximately $610.00, reflecting positive outlooks from healthcare and service sector researchers.
Identifying three specific equities to purchase at any given moment requires balancing robust fundamental growth drivers, solid balance sheets, and competitive market positioning across diverse economic sectors.
Chord Energy Corporation demonstrates strong operational and financial performance, highlighted by recent quarterly earnings reports that significantly surpassed Wall Street consensus estimates for both earnings per share and total revenues.
Chemed Corporation (NYSE: CHE) trades at $540.57 per share.
Chemed Corporation records annual revenues scaling approximately between USD 2.5 billion and USD 2.6 billion, driven by the robust performance of its two primary operating divisions: VITAS Healthcare and Roto-Rooter.